Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
176.5%
0%
176.5%
6 Months
0%
0%
0.0%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Rayzebio, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
-390.21%
EBIT to Interest (avg)
-39.47
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.94
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
95.26%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.63
EV to EBIT
-45.41
EV to EBITDA
-46.40
EV to Capital Employed
89.93
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-198.03%
ROE (Latest)
-11.92%
Technicals key factors
Indicator
Weekly
Monthly
MACD
RSI
Bearish
Bollinger Bands
Sideways
KST
Dow Theory
Bearish
OBV
No Trend
Shareholding Snapshot : Dec 2023
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 25 Schemes (10.08%)
Foreign Institutions
Held by 32 Foreign Institutions (6.53%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'22
Dec'22
Dec'21
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-70.60
-38.90
-81.49%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-68.60
-29.40
-133.33%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2022 is 0.00% vs 0.00% in Dec 2021
Consolidated Net Profit
YoY Growth in year ended Dec 2022 is -133.33% vs -326.09% in Dec 2021
About Rayzebio, Inc. 
Rayzebio, Inc.
Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






